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Can Stents Damage Coronary
Arteries Remote from the Stent?*
Gregory D. Tilton, MD, FACC
Metairie, Louisiana
During the past decade, cardiovascular stents and endothe-
lial function have both been the focus of intense research.
Because percutaneous coronary interventions tend to be
focal or “spot” therapy designed to open a relatively limited
vascular segment, the interaction between interventional
devices and the endothelium has focused almost exclusively
on the site of contact (1–4). Interventionalists know well
the problems that can occur at the site of stent contact with
the endothelium and the rest of the vessel wall in the form
of dissection, thrombosis and restenosis. The report by
Caramori et al. (5) in this issue of the Journal challenges us
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to broaden our view of the extent of the interaction between
coronary stent and endothelium and raises questions about
possible long-term negative effects remote from the stented
coronary segment.
This article (5) examines the coronary vasomotion of the
left anterior descending coronary artery in 39 patients
subclassified into three groups according to the type of
percutaneous intervention: Palmaz-Schatz stent, balloon
angioplasty or directional atherectomy. No patient had
restenosis an average of 19 months after the procedure.
Endothelial reactivity was measured at a segment distal to
the treated lesion and quantified by the degree of angio-
graphic spasm or dilation induced by intracoronary acetyl-
choline, which acts directly on the endothelium. The group
receiving stents had twice as much distal spasm as the other
two groups (22% vs. 9%). Stenting was the only variable
associated with this marker of endothelial dysfunction.
Two questions need to be asked. First, are the results real
or a function of the limitations of this well-executed original
study? Second, why should endothelial dysfunction distal to
the stent concern us? As the authors point out, the study’s
main limitation is the lack of randomization. But even if the
patients had been randomized, the potential for bias re-
mains substantial when trying to control for so many
variables that influence endothelial function in three small
groups. These factors include smoking, hypertension, lipid
status, vitamins C and E, angiotensin-converting enzyme
inhibitors, dilated cardiomyopathy and diabetes mellitus (6).
These seemed to favor no group, or perhaps the stent group
to a small degree. To neutralize the potential bias of these
factors that influence endothelial function, the authors used
as a control the circumflex artery reactivity, which was equal
in all groups. This decreases but does not eliminate the
concern about unequal baseline endothelial function in the
study groups.
Some questions remain about the methods used for the
arterial diameter measurements. A technician blinded to
treatment performed measurements. One must assume that
the frames used for measurement did not include the stent,
which could be visible to the technician. In addition, the
criteria used to select the segments for diameter measure-
ment are never discussed. Both of these factors could bias
diameter measurements. Two patients in the stent group
and one in the balloon angioplasty group required nitro-
glycerin to reverse intense spasm at the 1025 molar dose of
acetylcholine. It is unclear how the results from these
patients were treated, because the significant difference in
the study was evaluated at the 1024 molar dose, which was
not given to these three patients. Considering the small
number of patients in each group, the inclusion or exclusion
of the data from these patients might have an important
influence on the results. Finally, the small difference be-
tween the stent group and the other two groups needs to be
viewed cautiously owing to the inherent limitations in
quantitative angiography using automated edge detection.
Despite these questions, the findings cannot be dismissed
as due to chance or potential limitations in methodology.
Every patient in the stent group developed vasoconstriction
with high dose acetylcholine, whereas the other two groups
had heterogeneous reactions. It now serves as the gold
standard until further studies confirm or refute its conclu-
sion.
This study joins growing published data suggesting that
stents cause more coronary trauma and endothelial dysfunc-
tion than other types of percutaneous interventions (1,7).
But this study is novel in suggesting that stents may cause
more severe endothelial dysfunction than other types of
percutaneous interventions remote from the interventional
site. As the authors discuss, stents may adversely affect
endothelial function by inhibiting complete endothelial
regeneration and promoting excessive inflammatory cell
infiltration at the site of injury. The mechanisms by which
these local responses might modulate endothelial function
downstream remains to be defined.
Because endothelial dysfunction is intimately linked to
the initiation and progression of atherosclerotic coronary
artery disease (CAD) (8), this study raises the specter that
stents may promote CAD in the distal coronary artery. This
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could be a significant limitation for a therapeutic modality
that is spot therapy for a diffuse process such as CAD and
could threaten to limit the long-term efficacy of the proce-
dure.
The competition between coronary artery bypass grafting
surgery (CABG) and percutaneous interventions for the
treatment of advanced multivessel CAD has been enjoined
for some time. Even with just plain old balloon angioplasty,
percutaneous intervention has achieved intermediate-term
results similar to CABG with regard to death and major
infarction (9), except in certain diabetic patients. There has
been a realistic optimism among cardiologists that stents
will make percutaneous intervention even more competitive
with CABG. Until venous bypass grafts begin to degener-
ate, spot therapy with any percutaneous intervention has
two disadvantages compared with successful CABG. The
first is restenosis. The second is the failure to neutralize
plaque progression or rupture in the proximal epicardial
artery where the majority of these two events occur (10).
Therefore, progressive CAD proximal to a graft has little
impact on the efficacy of CABG, while significantly limiting
the durability of percutaneous interventions. If stents cause
significant acceleration of CAD distally, this would create a
third obstacle to overcome relative to CABG.
Aside from atherogenesis, endothelial dysfunction can
promote coronary thrombosis and reduce coronary flow
reserve. There is certainly no reported evidence of stents
causing such problems distal to the device. Therefore, the
finding of this study needs to be verified and the potential
effects of remote stent-induced endothelial dysfunction will
have to be investigated. To begin to determine if stents
induce distal atherosclerosis, it may be possible to turn to
centers with large volumes of long-term follow-up angio-
grams of patients who have received stents. By matching
them with appropriate control subjects, the potential prob-
lem of distal progression of CAD could be studied. Doppler
technology may also be useful to investigate functional
changes.
In the U.S., stents were used in over 50% of all percuta-
neous interventions in 1997. Although some question this
high incidence of stent usage, there are many excellent
reasons to support this practice. Stents have performed
significantly better than balloon angioplasty in multiple
randomized trials in a variety of clinical settings (11–14).
Randomized and nonrandomized studies have shown that
current techniques for deploying stents have substantially
reduced acute complications such as abrupt vessel closure,
in-hospital myocardial infarction, emergency CABG, re-
stenosis and target vessel revascularization. The cost-
effectiveness of stents versus balloon angioplasty is now
becoming apparent as the need for chronic anticoagulation
has disappeared and as longer term follow-up has been
achieved (15).
Despite the data justifying the high usage of stents, we
must continue to monitor for long-term complications
unique to either stents in general or a particular stent design.
Caramori et al.’s (5) report sounds a warning volley.
Whether or not it is a false alarm remains to be determined.
However, this theoretical concern will not curb stent usage
with its proven benefits until meaningful disadvantages are
firmly demonstrated.
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